The development of neural stem cell therapies holds significant potential for treating a wide range of neurological disorders and injuries. However, scientific uncertainties surround the use of induced pluripotent stem cells (iPSCs) and directly reprogrammed stem cells derived from patient somatic cells. Primary concerns include the risk of tumorigenesis or immune rejection due to potential instabilities in chromosomal DNA and the differentiation capacity of these cells into target cell types. Additionally, non-scientific challenges arise from the novelty of using induced neural stem cells as a form of cell therapy and from misconceptions and unfounded fears among patients regarding the safety of stem cell therapies. iNStemCARE is dedicated to overcoming the scientific and regulatory challenges associated with developing neural stem cell therapies for rare and neurodegenerative diseases. “We are at the forefront of advancing next-generation neural stem cell therapeutics,” says CTO and founder Sunghoi Hong. “We seek to revolutionize the treatment landscape for conditions that have long been deemed incurable.” Taking a Proactive Approach to Neural Stem Cell Therapeutics iNStemCARE is committed to continuous research and development, meticulously gathering and analyzing data to meet the stringent requirements of regulatory bodies. By sharing this data with patients and the broader medical community, the company aims to demonstrate the safety and high efficacy of its neural stem cell therapies, dispelling misconceptions and building trust in their groundbreaking approach. A key differentiator for iNStemCARE is its patented technology for maintaining the stability of chromosomal DNA in reprogrammed cells. Ensuring that these cells remain free from fatal mutations is a crucial prerequisite for developing safe and effective cell therapies. Mutations in cellular DNA pose serious safety risks, such as the potential for cancer development, and impair th